Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)
10th July 2020
Portfolio
This post references, or is about AtoxBio. Find out more by clicking below
Print Article
Email Article
Save Article
Stay Updated
Add your email below to stay updated with useful and informative content from Arix and our portfolio companies
